ARTICLE | Targets & Mechanisms

A new boost from sildenafil

October 14, 2010 7:00 AM UTC

Pfizer Inc.'s vasodilator sildenafil, marketed as Viagra for erectile dysfunction and as Revatio to treat pulmonary arterial hypertension, also could have utility in oncology, according to new findings by researchers at Virginia Commonwealth University. The team found that sildenafil has a unique synergy with doxorubicin: it not only reduces the chemotherapeutic's cardiotoxicity but also potentiates its efficacy.1

Doxorubicin is widely used in a host of cancers, but the drug's label includes a boxed warning of myocardial toxicity, including potentially fatal congestive heart failure (CHF)...